WO2009014642A1 - Combinaisons pour le traitement du cancer - Google Patents

Combinaisons pour le traitement du cancer Download PDF

Info

Publication number
WO2009014642A1
WO2009014642A1 PCT/US2008/008769 US2008008769W WO2009014642A1 WO 2009014642 A1 WO2009014642 A1 WO 2009014642A1 US 2008008769 W US2008008769 W US 2008008769W WO 2009014642 A1 WO2009014642 A1 WO 2009014642A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
pyridin
usa
mtap
purine biosynthesis
Prior art date
Application number
PCT/US2008/008769
Other languages
English (en)
Inventor
Alexander Kamb
Astrid Ruefli-Brasse
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of WO2009014642A1 publication Critical patent/WO2009014642A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention is in the field of pharmaceutical agents and specifically relates to combinations, compositions, uses and methods for treating cancer.
  • Cyclin dependent kinases play a key role in regulating the cell cycle. They consist of a catalytic subunit (the kinase) and a regulatory subunit (the cyclin). Kinase subunits (e.g. cdk 1-9) have been identified along with several regulatory subunits (cyclins A-H).
  • Each kinase associates with a specific regulatory partner and together make up the active catalytic moiety.
  • Each transition of the cell cycle is regulated by a particular cdk complex: Gll/S by cdk2/cyclin E, cdk4/cyclin Dl and cdk ⁇ /cyclin D2; S/G2 by cdk2/cyclin A and cdkl/cyclin A; G2/M by cdkl/B.
  • the coordinated activity of these kinases guides the individual cells through the replication process and ensures the vitality of each subsequent generation.
  • inhibitors include p 16 INK4 (an inhibitor of cdk4/Dl), p 21 CIPl (a general cdk inhibitor), and p 27 KIPl (a specific cdk2/E inhibitor). These proteins help to regulate the cell cycle through specific interactions with their corresponding cdk complexes. Cells deficient in these inhibitors are prone to unregulated growth and tumor formation.
  • MTAP methylthioadenosine phosphorylase
  • AdSL Adenylosuccinate lyase
  • SACAIR 5-aminoimidazole-4-(N-succinylocarbxamide) ribotide
  • ACAIR 5-aminoimidazole-4-carboxamide ribotide
  • SAMP adenylosuccinate
  • AMP adenosine monophosphate
  • AdSS adenylosuccinate synthase
  • Salvage of ATP occurs through a series of biosynthetic steps culminating in production of AMP from 5-deoxy-5- methylthioadenosine (MTA) by action of the enzyme MTAP.
  • MTA 5-deoxy-5- methylthioadenosine
  • Figure 1 shows the dose response of a CDK inhibitor in MT AP+/+ or
  • Figure 2 shows the combination of a CDK inhibitor with alanosine in
  • CDK inhibitor and alanosine T - CDK inhibitor; alanosine and adenine; ⁇ - CDK inhibitor and adenine
  • Figure 3 shows the combination of a CDK inhibitor with alanosine in
  • MTAP "A MiaPaCa cells with or without 20 ⁇ M adenine. [ ⁇ - CDK inhibitor alone; ⁇
  • CDK inhibitor and alanosine T - CDK inhibitor; alanosine and adenine; ⁇ - CDK inhibitor and adenine
  • Figure 4 shows the combination of a CDK inhibitor with alanosine in
  • CDK inhibitor and alanosine T - CDK inhibitor; alanosine and MTA; ⁇ - CDK inhibitor and MTA]
  • Figure S shows the combination of a CDK inhibitor with alanosine in
  • MTAP ' ' ' MiaPaCa cells with or without 20 ⁇ M MTA.
  • ⁇ - CDK inhibitor alone; ⁇ - CDK inhibitor and alanosine; ⁇ - CDK inhibitor; alanosine and MTA; ⁇ - CDK inhibitor and MTA [ ⁇ - CDK inhibitor alone; ⁇ - CDK inhibitor and alanosine; ⁇ - CDK inhibitor; alanosine and MTA; ⁇ - CDK inhibitor and MTA]
  • Figure 6 shows the combination of a CDK inhibitor with thymidine (20 ⁇ M) with and without methotrexate (MTX, 20 nM (IC 20 )) on MTAP +/+ MiaPaCa cells.
  • Figure 7 shows the combination of a CDK inhibitor with thymidine (20 ⁇ M) with and without methotrexate (MTX, 20 nM (IC 20 )) on MTAP 7' MiaPaCa cells.
  • the present invention is generally directed to compositions and methods for reducing tumor growth, and generally treating tumors in animals, including humans.
  • the present invention is the determination that a combination of at least one agent that inhibits the de novo purine biosynthesis and at least one agent that inhibits CDK4 and/or CDK6 provides a beneficial effect.
  • the results obtained indicate that targeting both CDK4/6 and de novo AMP biosynthesis has a heightened effect in tumors pre-selected for loss of pl6 and MTAP. This result is unexpected because it has been assumed that CDK4/6 antagonism would be cytostatic, and might actually protect cells from agents that diminish AMP synthesis.
  • the present invention offers a surprising benefit from the combination of at least one agent that inhibits the de novo purine biosynthesis and at least one agent that inhibits CDK4 and/or CDK6, and that therapies which involve administration of combinations of these agents are beneficial in the treatment of cancer.
  • the surprising benefit between the individual agents tested provide a number of unforeseen options for the treatment of tumors or cancers.
  • Inhibitors against enzymes in the de novo pathway will kill MTAP- deficient (MTAP * ' ) tumors, while leaving the salvage pathway intact in MTAP-positive (MTAP +/+ ) cells, providing a source of ATP for normal tissues.
  • the de novo purine biosynthesis pathway includes several key points for intervention. For example, adenylosuccinate synthetase (AdSS) and adenylosuccinate lyase (AdSL) catalyze the conversion of IMP to adenylsuccinate and AMP.
  • AdSS adenylosuccinate synthetase
  • AdSL adenylosuccinate lyase
  • AdSL also catalyses the conversion of succinylaminoimidazole-carboxide ribotide (SAICAR) to aminoimidazolecarboxamide ribotide (AICAR). Therefore an agent that inhibits AdSS is included in this invention. Alternatively, an agent that inhibits AdSL is included in this invention.
  • SAICAR succinylaminoimidazole-carboxide ribotide
  • AICAR aminoimidazolecarboxamide ribotide
  • MTAP functions in both purine and polyamine metabolism in rapidly dividing cells. Tumors that have lost MTAP rely on the de novo pathway for ATP production. The absence of MTAP distinguishes some leukemic cells in vivo from their nonmalignant counterparts. Many other tumors lack MTAP due to homozygous deletion.
  • Inhibitors against enzymes in the de novo pathway include an adenine biosynthesis inhibitor such as alanosine, SDX- 102 (the L-isomer of alanosine, which was under development by Cephalon for the treatment of cancer and the like).
  • alanosine the L-isomer of alanosine, which was under development by Cephalon for the treatment of cancer and the like.
  • Formulations for L-alanosine are described in US2006/0041013.
  • Methotrexate (MTX) has been found to interfere with de novo purine synthesis by inhibiting dhfr and reducing the available folate required for several of the enzymatic reactions involved in the biochemical pathway.
  • Other inhibitors of de novo purine synthesis are described in US Pat. No. 7,157,551.
  • CDK4/6 inhibitors are especially attractive as anti-cancer therapies because of somatic mutations that are believed to activate (or more precisely, relieve their inhibition) which occur in a high proportion of cancers.
  • Agents known to inhibit CDK4 and or CDK6 include:
  • GW-491619 a CDK4 inhibitor, under development by GlaxoSmithKline for the treatment of cancer
  • NU-6027 a cyclin dependent kinase (CDK) inhibitor under investigation by
  • AstraZeneca for use in cancer AG-12275 (a selective CDK4 inhibitor under investigation by Pfizer for the treatment of cancer); AG-12286 (a broad-spectrum CDK4 inhibitor under investigation by Pfizer for the treatment of cancer); PD-Ol 66285 (a cyclin A-mediated inhibitor of CDK4 under investigation by
  • PD-0332991 a highly-specific CDK4/6 inhibitor, under development by Pfizer for the treatment of cancer
  • Alvocidib flavopiridol; HMR-1275, an inhibitor of Cdk4 under development by
  • CDK4/6 inhibitors are described in WO 03/062236. Examples of such inhibitors include:
  • N4-Cyclopentyl-5-iodo-N-2-(5-piperazin-l-yl-pyridin-2-yl)-pyrimidine-2,4-diamine N4-Cyclopentyl-5-iodo-N-2-(lH-pyrrolo[3,2-b]pyridin-5-yl)-pyrimidine-2,4-diamine, 4-[6-(5-Bromo-4-cyclopentylamino-pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-l- carboxylic acid tert-butyl ester, 4-[6-(4-Cyclopentylamino-5-formyl-pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-
  • CDK4 inhibitors can be prepared based on the descriptions found in US
  • WO02/96888 WO03/076437, WO03/76436, WO03/76434, and WO01/64368.
  • a simple diagnostic test can target tumors that are (i) dependent on CDK4/6; and (ii) dependent on de novo AMP synthesis.
  • another aspect of the present invention comprises treatment of a cancer that activates a CDK protein such as CDK4/6, that also under-expresses MTAP.
  • the invention also comprises usage of a rescue substrate, such as MTA,
  • EFA 9- ⁇ -D-erythrofuranosyladenine
  • adenine 9- ⁇ -D-erythrofuranosyladenine
  • 5840505 and 6214571 describe the treatment of alanosine treated cells with MTA.
  • WO03/074083 describes various MTA derivatives that should be useful as rescue substrates.
  • the invention also relates to treatment of neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of the bladder, breast, colon (including colorectal cancer), kidney, head and neck, liver, lung (including non- small cell lung cancer), esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin (including squamous cell carcinoma); hematopoietic tumors of lymphoid lineage (including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma); hematopoietic tumors of myeloid lineage (including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promy
  • tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma and schwannomas); and other tumors (including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma).
  • the invention also relates to treatment of neoplasias that are MTAP deficient. Possible patients can be tested to determine whether they have cancer cells that are homozygous for MTAP deficiency. MTAP deficiency also includes cells where the MTAP expression and or activity is partially reduced, substantially reduced or eliminated. Such deficiency means that the cells ability to replenish the adenine pool is negatively impacted.
  • the present invention includes a method for prognostic or diagnostic assessment of a neoplastic disorder in a subject, comprising: a) preparing a sample of nucleic acids from a specimen obtained from the subject; b) contacting the sample with a panel of nucleic acid segments consisting of at least 2 members from the group consisting of p 16, CDK4, CDK6, and MTAP to detect the levels of the panel segments; c) evaluating the sample against a reference standard to determine the magnitude of change in the amounts of the at least 2 members present in the sample; and d) correlating the magnitude of change with the presence or resolution of the disorder.
  • the invention also relates to a method for prognostic or diagnostic assessment wherein the detection identifies a disorder that is likely to respond to a composition comprising at least one de novo purine biosynthesis inhibitor and at least one CDK inhibitor.
  • the invention also relates to the use of the combination of at least one de novo purine biosynthesis with at least one CDK4 and/or CDK6 inhibitor in adjuvant or neoadjuvant chemotherapy, with or without radiation, for the treatment of neoplasia.
  • adjuvant chemotherapy is defined as the continued treatment after either intensive cycles of chemotherapy and/or radiation, or alternatively after surgery to remove tumors. Alternatively the term describes the use of drugs as additional treatment for patients with cancers that are thought to have spread outside their original sites.
  • Neo-adjuvant therapy is defined as intensive cycles of chemotherapy and/or radiation given to reduce the size of tumor before a definitive surgery.
  • Such adjuvant or neo-adjuvant chemotherapy +/- radiation relates to the treatment of neoplasia including, but not limited to: carcinoma of the breast, colon, lung, and head and neck.
  • the invention is also directed to a method of administration of the combination. More particularly the active agents of the combination therapy are administered sequentially in either order or simultaneously. When the active agents are administered simultaneously, one skilled in the art will understand that the second agent can be administered some time after the first agent. The particular period of delay is dependent on the particular pharmacokinetic and formulation parameters of the active agent.
  • the invention also relates to treatment wherein the de novo purine synthesis inhibitor is pre-dosed (administered first), followed by treatment with the CDK4 or CDK6 inhibitor. Alternatively the pre-dose may occur 24-48 hours prior to the treatment with the CDK4 or CDK6 inhibitor.
  • the invention also relates to a kit, wherein the inhibitors are disposed in separate containers.
  • the invention also relates to a kit according to any of the foregoing, further comprising integrally thereto or as one or more separate documents, information pertaining to the contents or the kit and the use of the inhibitors.
  • the term “treating” or “treatment” and the like should be taken broadly. They should not be taken to imply that an animal is treated to total recovery. Accordingly, these terms include amelioration of the symptoms or severity of a particular condition or preventing or otherwise reducing the risk of further development of a particular condition.
  • neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm.
  • methods of the invention may be applicable to various species of subjects, preferably mammals, more preferably humans.
  • the compounds of the present invention include the pharmaceutically acceptable derivatives thereof.
  • CDK inhibitor means a compound that inhibits CDK4, CDK6 or both CDK4/CDK6.
  • cancer and “cancerous” when used herein refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • cancer include but are not limited to, carcinoma, lymphoma, sarcoma, blastoma and leukemia. More particular examples of such cancers include squamous cell carcinoma, lung cancer, pancreatic cancer, cervical cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, and head and neck cancer.
  • a “pharmaceutically-acceptable derivative” denotes any salt, ester of a compound of this invention, or any other compound which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof.
  • pharmaceutically-acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases.
  • the nature of the salt is not critical, provided that it is pharmaceutically-acceptable.
  • Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
  • organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic, pantothenic, 2- hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, camphoric, camphors
  • Suitable pharmaceutically- acceptable base addition salts include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, aistidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, trimethylamine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of the invention. When a basic group and an acid group are present in the same molecule, a compound of the invention may also form internal salts.
  • antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy.
  • Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous agents.
  • a first family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents.
  • Suitable antimetabolite antineoplastic agents may be selected from but not limited to the group consisting of 5-FU, fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP- 30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co.
  • EX-Ol 5 isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, norspermidine, NCI NSC- 127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC-788, thioguar ⁇ ne, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, Taiho UFT and uricytin.
  • a second family of antineoplastic agents which may be used in combination with compounds of the present invention consists of alkylating-type antineoplastic agents.
  • Suitable alkylating-type antineoplastic agents may be selected from but not limited to the group consisting of Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine, Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto DACHP(Myr)2, diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI
  • a third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents.
  • Suitable antibiotic-type antineoplastic agents may be selected from but not limited to the group consisting of Taiho 4181 -A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol- Myers BMY-26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chro
  • a fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous family of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from but not limited to the group consisting of ⁇ -carotene, ⁇ -difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston AlO, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015
  • the combination of the present invention comprises a composition of the present invention in combination with at least one anti-tumor agent.
  • Agents are inclusive of, but not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof.
  • An agent can be an agonist, antagonist, allosteric modulator, toxin or, more generally, may act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition), and thereby promote cell death or arrest cell growth.
  • anti-tumor agents include HERCEPTINTM (trastuzumab), which may be used to treat breast cancer and other forms of cancer, and RITUXANTM (rituximab), ZEVALINTM (ibritumomab tiuxetan), and LYMPHOCIDETM (epratuzumab), which may be used to treat non-Hodgkin's lymphoma and other forms of cancer, GLEEV ACTM which may be used to treat chronic myeloid leukemia and gastrointestinal stromal tumors, and BEXXARTM (iodine 131 tositumomab) which may be used for treatment of non-Hodgkins's lymphoma.
  • anti-angiogenic agents include ERBITUXTM (MC-C225),
  • KDR (kinase domain receptor) inhibitory agents e.g., antibodies and antigen binding regions that specifically bind to the kinase domain receptor
  • anti-VEGF agents e.g., antibodies or antigen binding regions that specifically bind VEGF, or soluble VEGF receptors or a ligand binding region thereof
  • AVASTINTM or VEGF-TRAPTM e.g., antibodies or antigen binding regions that specifically bind thereto
  • EGFR inhibitory agents e.g., antibodies or antigen binding regions that specifically bind thereto
  • anti-Angl and anti-Ang2 agents e.g., antibodies or antigen binding regions specifically binding thereto or to their receptors, e.g., Tie2/Tek
  • anti-Tie2 kinase inhibitory agents e.g., antibodies or antigen binding regions that specifically bind to the kinase domain receptor
  • anti-VEGF agents e.g., antibodies or antigen binding regions that specifically bind VEGF, or
  • compositions of the present invention can also include one or more agents (e.g., antibodies, antigen binding regions, or soluble receptors) that specifically bind and inhibit the activity of growth factors, such as antagonists of hepatocyte growth factor (HGF, also known as Scatter Factor), and antibodies or antigen binding regions that specifically bind its receptor "c-met".
  • agents e.g., antibodies, antigen binding regions, or soluble receptors
  • HGF hepatocyte growth factor
  • c-met hepatocyte growth factor
  • Other anti-angiogenic agents include Campath, EL-8, B-FGF, Tek antagonists (Ceretti et al., US Publication No. 2003/0162712; US Patent No. 6,413,932), anti-TWEAK agents (e.g., specifically binding antibodies or antigen binding regions, or soluble TWEAK receptor antagonists; see, Wiley, US Patent No.
  • ADAM distintegrin domain to antagonize the binding of integrin to its ligands (Fanslow et al., US Publication No. 2002/0042368), specifically binding anti-eph receptor and/or anti-ephrin antibodies or antigen binding regions (U.S. Patent Nos.
  • anti-PDGF-BB antagonists e.g., specifically binding antibodies or antigen binding regions
  • antibodies or antigen binding regions specifically binding to PDGF-BB ligands
  • PDGFR kinase inhibitory agents e.g., antibodies or antigen binding regions that specifically bind thereto
  • Additional anti-angiogenic/anti-tumor agents include: SD-7784 (Pfizer,
  • the present combinations may also be used in co-therapies with other anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A), daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docos
  • the present compounds may also be used in conjunction with agents used for hormonal therapy, such as for treatment of breast and prostate cancer.
  • agents used for hormonal therapy such as for treatment of breast and prostate cancer.
  • agents used for hormonal therapy include aromatase inhibitors (e.g. Arimidex (chemical name: anastrozole), Aromasin (chemical name: exemestane), and Femara (chemical name: letrozole)); Serms (selective estrogen-receptor modulators) such as tamoxifen; and ERDs (estrogen-receptor downregulators), e.g. Faslodex (chemical name: fulvestrant).
  • Arimidex chemical name: anastrozole
  • Aromasin chemical name: exemestane
  • Femara chemical name: letrozole
  • Serms selective estrogen-receptor modulators
  • tamoxifen e.g. Faslodex (chemical name: fulvestrant).
  • Faslodex chemical name:
  • the dose of a combination of the present invention to be administered, the period of administration, and the general administration regime may differ between subjects depending on such variables as the severity of symptoms, the type of tumor to be treated, the mode of administration chosen, type of composition, size of a unit dosage, kind of excipients, the age and/or general health of a subject, and other factors well known to those of ordinary skill in the art.
  • Administration may include a single daily dose or administration of a number of discrete divided doses as may be appropriate.
  • An administration regime may also include administration of one or more of the active agents, or compositions comprising same, as described herein.
  • the period of administration may be variable. [0059] It may occur for as long a period is desired.
  • Administration may include simultaneous administration of suitable agents or compositions or sequential administration of agents or compositions.
  • compositions comprising the active inhibitors in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier” materials) and, if desired, other active ingredients.
  • carrier non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants
  • the active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • the compounds and compositions of the present invention may, for example, be administered orally, mucosally, topically, rectally, pulmonarily such as by inhalation spray, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly intrasternally and infusion techniques, in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.
  • the pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
  • dosage units are tablets or capsules.
  • these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg.
  • a suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.
  • the amount of compounds which are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods.
  • a daily dose of about 0.01 to 500 mg/kg, preferably between about 0.01 and about 50 mg/kg, and more preferably about 0.01 and about 30 mg/kg body weight may be appropriate.
  • the daily dose can be administered in one to four doses per day.
  • the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
  • the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
  • Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
  • Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers.
  • Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • the active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (ie. Captisol), cosolvent solubilization (ie. propylene glycol) or micellar solubilization (ie. Tween 80).
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
  • a non-toxic parenterally acceptable diluent or solvent for example as a solution in 1 ,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed, including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of i ⁇ jectables.
  • the pharmaceutical composition may be administered in the form of an aerosol or with an inhaler including dry powder aerosol.
  • the pharmaceutical compositions may be subj ected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings.
  • Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.
  • kits comprising one or more de novo purine biosynthesis inhibitor with one or more CDK4 and/or CDK6 inhibitor in accordance with the foregoing.
  • the inhibitors may be disposed in the kits in one or more containers. Each such container may contain separately or in admixture one or more de novo purine biosynthesis inhibitor and one or more CDK4 and/or CDK6 inhibitor in accordance with any of the foregoing.
  • such kits are designed for medical use, and the inhibitors are comprised in pharmaceutically acceptable formulations.
  • kits wherein the inhibitors are disposed in separate containers.
  • kits are those that comprise integrally thereto or as one or more separate documents, information pertaining to the contents or the kit and the use of the inhibitors. Also among the kits are those wherein the compositions, if injectable, are formulated for reconstitution in a diluent. In this regard, kits further comprising one or more containers of sterile diluent are also included.
  • the present invention also includes kits wherein at least one of the inhibitors can be disposed in vials under partial vacuum sealed by a septum and suitable for reconstitution to form a formulation effective for parental administration.
  • the present invention also includes kits wherein at least one of the inhibitors is in tablet form.
  • kits that provide single-dose packaging of one or more of the inhibitors.
  • MiaPaCa-2 pancreatic cells which harbor a homozygous deletion in MTAP (MTAP "7" ) were obtained from ATCC. Cells were infected with either a control virus (pLPC) or a virus expressing MTAP (pLPC-MTAP). Infected cells were selected by puromycin resistance and maintained in 0.5 ⁇ g/ml puromycin. MTAP expression in MTAP +/+ MiaPaCa-2 cells was confirmed by QPCR.
  • CDK4 inhibitor in MTAP +/+ and MTAP 7" MiaPaCa-2 cells The
  • IC 50 of a CDK4 inhibitor was determined in the MTAP+/+ and MTAP-/- MiaPaCa-2 cells using a thymidine incorporation assay.
  • MTAP " ' " and MTAP +/+ MiaPaCa-2 cells from Example 1 were seeded at 2x10 4 cells/ml in 100 ⁇ l per well in Costar T plates (Amersham Biosciences). Twenty-four hours later a dose response of a CDK4 inhibitor PD-0332991 (1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations) was added to triplicate wells.
  • MTAP +/+ MiaPaCa-2 cells from Example 1 were seeded at 2x10 4 cells/ml in 100 ⁇ l per well in Costar T plates (Amersham Biosciences). Twenty-four hours later a dose response of a CDK4 inhibitor PD-0332991 (1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations) was added to triplicate wells with or without 1.7 ⁇ M (IC 20 ) of alanosine.
  • a CDK4 inhibitor PD-0332991 1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations
  • Some cells were also treated with 20 ⁇ M adenine (Sigma) as rescue substrate.
  • 14 C- Thymidine (0.1 ⁇ Ci, Amersham) was added to each well for a final total volume of 200 ⁇ L. Plates were read for incorporation of the radioactive thymidine as a measure of cell viability on a beta counter at time 0, 24, 48, 72 and 96 hours. Data was calculated as the mean and standard deviation of triplicate samples divided by the mean and standard deviation of untreated control samples to yield percent of control.
  • the IC 50 of the CDK4 inhibitor alone was 4.330 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the alanosine was 0.9955 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the alanosine and with adenine was 5.564 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the adenine was 7.356 ⁇ M. See Fig. 2.
  • Some cells were also treated with 20 ⁇ M adenine (Sigma) as rescue substrate.
  • 14 C-Thymidine (0.1 ⁇ Ci, Amersham) was added to each well for a final total volume of 200 ⁇ L. Plates were read for incorporation of the radioactive thymidine as a measure of cell viability on a beta counter at time 0, 24, 48, 72 and 96 hours. Data was calculated as the mean and standard deviation of triplicate samples divided by the mean and standard deviation of untreated control samples to yield percent of control.
  • the IC 5O of the CDK4 inhibitor alone was 1.276 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the alanosine was 0.2866 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the alanosine and with adenine was 2.458 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the adenine was 0.9495 ⁇ M. See Fig. 3.
  • MTAP +/+ MiaPaCa-2 cells from Example 1 were seeded at 2x10 4 cells/ml in 100 ⁇ l per well in Costar T plates (Amersham Biosciences). Twenty-four hours later a dose response of a CDK4 inhibitor PD-0332991 (1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations) was added to triplicate wells with or without 1.7 ⁇ M (IC 2 o) of alanosine.
  • PD-0332991 1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations
  • Some cells were also treated with 20 ⁇ M MTA (Sigma) as rescue substrate.
  • I4 C-Thymidine (0.1 ⁇ Ci, Amersham) was added to each well for a final total volume of 200 ⁇ L. Plates were read for incorporation of the radioactive thymidine as a measure of cell viability on a beta counter at time 0, 24, 48, 72 and 96 hours. Data was calculated as the mean and standard deviation of triplicate samples divided by the mean and standard deviation of untreated control samples to yield percent of control.
  • the IC 50 of the CDK4 inhibitor alone was 4.330 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the alanosine was 0.9955 ⁇ M.
  • the IC 5 O of the CDK4 inhibitor together with the alanosine and with MTA was 6.104 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the MTA was 8.253 ⁇ M. See Fig. 4.
  • MTAP ' ' ' MiaPaCa-2 cells from Example 1 were seeded at 2xlO 4 cells/ml in 100 ⁇ l per well in Costar T plates (Amersham Biosciences). Twenty-four hours later a dose response of a CDK4 inhibitor PD-0332991 (1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations) was added to triplicate wells with or without 1.7 ⁇ M (IC 2 o) of alanosine.
  • PD-0332991 1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations
  • Some cells were also treated with 20 ⁇ M MTA (Sigma) as rescue substrate.
  • 14 C-Thymidine (0.1 ⁇ Ci, Amersham) was added to each well for a final total volume of 200 ⁇ L. Plates were read for incorporation of the radioactive thymidine as a measure of cell viability on a beta counter at time 0, 24, 48, 72 and 96 hours. Data was calculated as the mean and standard deviation of triplicate samples divided by the mean and standard deviation of untreated control samples to yield percent of control.
  • the IC 50 of the CDK4 inhibitor alone was 1.276 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the alanosine was 0.2866 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the alanosine and with MTA was 0.6432 ⁇ M.
  • the IC 50 of the CDK4 inhibitor together with the MTA was 1.707 ⁇ M. See Fig. 5.
  • MiaPaCa-2 cells from Example 1 were seeded at 2x10 4 cells/ml in 100 ⁇ l per well in Costar T plates (Amersham Biosciences). Twenty-four hours later a dose response of a CDK4 inhibitor PD-0332991 (1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations) and thymidine (20 ⁇ M, Sigma) was added to triplicate wells with or without 20 nM (IC 20 ) of MTX. 14 C-Thymidine (0.1 ⁇ Ci, Amersham) was added to each well for a final total volume of 200 ⁇ L.
  • a CDK4 inhibitor PD-0332991 1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇
  • MiaPaCa-2 cells from Example 1 were seeded at 2x10 4 cells/ml in 100 ⁇ l per well in Costar T plates (Amersham Biosciences). Twenty-four hours later a dose response of a CDK4 inhibitor PD-0332991 (1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M concentrations) and thymidine (20 ⁇ M, Sigma) was added to triplicate wells with or without 20 nM (IC 20 ) of MTX. 14 C-Thymidine (0.1 ⁇ Ci, Amersham) was added to each well for a final total volume of 200 ⁇ L.
  • a CDK4 inhibitor PD-0332991 1 nM; 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention relève du domaine des agents pharmaceutiques et concerne, plus spécifiquement, des combinaisons, des compositions, des utilisations et des procédés pour traiter le cancer.
PCT/US2008/008769 2007-07-19 2008-07-17 Combinaisons pour le traitement du cancer WO2009014642A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96127807P 2007-07-19 2007-07-19
US60/961,278 2007-07-19

Publications (1)

Publication Number Publication Date
WO2009014642A1 true WO2009014642A1 (fr) 2009-01-29

Family

ID=39876734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/008769 WO2009014642A1 (fr) 2007-07-19 2008-07-17 Combinaisons pour le traitement du cancer

Country Status (2)

Country Link
US (1) US20090030005A1 (fr)
WO (1) WO2009014642A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150925A2 (fr) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Palbociclib deutéré
EP3050567A1 (fr) * 2013-09-26 2016-08-03 Energenesis Biomedical Co., Ltd. Composé servant à l'activation de l'ampk et ses utilisations

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085185A1 (fr) * 2007-12-19 2009-07-09 Amgen Inc. Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
US8389533B2 (en) * 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
ES2620521T3 (es) 2011-03-23 2017-06-28 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014081953A1 (fr) 2012-11-21 2014-05-30 Richard David J Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 et des dérivés d'isoquinoléine et de quinoléine
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
WO2015061348A1 (fr) * 2013-10-21 2015-04-30 Memorial Sloan-Kettering Cancer Center L'atrx comme diagnostic compagnon pour des inhibiteurs de cdk4
WO2015066305A1 (fr) * 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Procédés de détermination de la chimiosensibilité et de la chimiotoxicité
WO2016024249A1 (fr) * 2014-08-14 2016-02-18 Sun Pharmaceutical Industries Limited Formes cristallines de palbociclib
CA2974240A1 (fr) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Essai de diagnostic dependant du contexte pour guider le traitement du cancer
RU2717829C2 (ru) 2015-04-20 2020-03-26 Толеро Фармасьютикалз, Инк. Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
WO2017024073A1 (fr) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Thérapies combinatoires pour le traitement du cancer
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018059216A1 (fr) * 2016-09-29 2018-04-05 广州君赫生物科技有限公司 Composés réduisant l'activité de saicar synthase, et applications
WO2018094275A1 (fr) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
MX2019007332A (es) 2016-12-19 2019-11-18 Tolero Pharmaceuticals Inc Péptidos indicadores y métodos para caracterizar sensibilidad.
US11517541B2 (en) 2017-04-20 2022-12-06 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
EP3890749A4 (fr) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4370126A1 (fr) * 2021-07-16 2024-05-22 Dana-Farber Cancer Institute, Inc. Agents de dégradation de la kinase dépendante de la cycline 4/6 (cdk4/6) et ikzf2 (helios) à petites molécules et leurs procédés d?utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091127A1 (en) * 2000-12-08 2002-07-11 Carini David J. Semicarbazides and their uses
US20050164976A1 (en) * 2002-03-15 2005-07-28 Cyclacel Limited Combination of a cdk inhibitor and 5-fu for the tratment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214571B1 (en) * 1993-12-29 2001-04-10 The Regents Of The University Of California Method for inhibiting adenylosuccinate synthetase activity in malignant methylthioadenosine phosphorylase deficient cells
US5840505A (en) * 1993-12-29 1998-11-24 The Regents Of The University Of California Method for inhibiting adenylosuccinate synthetase activity in methylthioadenosine phosphorylase deficient cells
US6689864B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Cyclin dependent kinase 4 inhibitor
JP4291135B2 (ja) * 2001-05-29 2009-07-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
US7157551B2 (en) * 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
US20060041013A1 (en) * 2004-08-18 2006-02-23 Brittain Jason E Alanosine formulations and methods of use
WO2007129062A1 (fr) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Combinaisons pharmaceutiques de dérivés de diazole pour le traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091127A1 (en) * 2000-12-08 2002-07-11 Carini David J. Semicarbazides and their uses
US20050164976A1 (en) * 2002-03-15 2005-07-28 Cyclacel Limited Combination of a cdk inhibitor and 5-fu for the tratment of cancer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BENTLEY JO ET AL: "ATP depletion potentiates the effect of the novel purine cyclin dependent kinase inhibitor NU6102", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 43, 1 March 2002 (2002-03-01), pages 324, XP001536898, ISSN: 0197-016X *
EFFERTH THOMAS ET AL: "Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells", BLOOD CELLS MOLECULES AND DISEASES, vol. 28, no. 1, January 2002 (2002-01-01), pages 47 - 56, XP002503865, ISSN: 1079-9796 *
HORI H ET AL: "METHYLTHIOADENOSINE PHOSPHORYLASE CDNA TRANSFECTION ALTERS SENSITIVITY TO DEPLETION OF PURINE AND METHIONINE IN A549 LUNG CANCER CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, USA, DE, vol. 56, no. 24, 15 December 1996 (1996-12-15), pages 5653 - 5658, XP000941602 *
HUSTINX STEVEN R ET AL: "Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy.", CANCER BIOLOGY & THERAPY JAN 2005, vol. 4, no. 1, January 2005 (2005-01-01), pages 83 - 86, XP002503864, ISSN: 1538-4047 *
ILLEIL ET AL: "O-29 The methylthioadenosine phosphorylase (MTAP) gene is homozygously co-deleted with CDKN2A in most pleural mesotheliomas. Detection by fluorescent in situ hybridization (FISH) and by immunohistochemistry (IHC) using a novel MTAP monoclonal antibody", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 41, 1 August 2003 (2003-08-01), pages S12, XP005874939, ISSN: 0169-5002 *
JOSHI KALPANA S ET AL: "In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.", MOLECULAR CANCER THERAPEUTICS MAR 2007, vol. 6, no. 3, March 2007 (2007-03-01), pages 918 - 925, XP002503867, ISSN: 1535-7163 *
KARIKARI COLLINS A ET AL: "Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers", MOLECULAR CANCER THERAPEUTICS, vol. 4, no. 12, December 2005 (2005-12-01), pages 1860 - 1866, XP002503866, ISSN: 1535-7163 *
KNOCKAERT M ET AL: "Pharmacological inhibitors of cyclin-dependent kinases", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 23, no. 9, 1 September 2002 (2002-09-01), pages 417 - 425, XP004381043, ISSN: 0165-6147 *
KONG NORMAN ET AL: "Cell cycle inhibitors for the treatment of cancer.", DRUGS OF THE FUTURE, vol. 28, no. 9, September 2003 (2003-09-01), pages 881 - 896, XP002503863, ISSN: 0377-8282 *
MIREBEAU DELPHINE ET AL: "The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.", HAEMATOLOGICA JUL 2006, vol. 91, no. 7, July 2006 (2006-07-01), pages 881 - 885, XP002503868, ISSN: 1592-8721 *
SHAH ET AL: "Cyclin dependent kinases as targets for cancer therapy", UPDATE ON CANCER THERAPEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 3, 1 September 2006 (2006-09-01), pages 311 - 332, XP005657023, ISSN: 1872-115X *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150925A2 (fr) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Palbociclib deutéré
EP3492470A1 (fr) 2013-03-15 2019-06-05 Concert Pharmaceuticals, Inc. Palbociclib deutéré avec une stabilité métabolique améliorée
EP3050567A1 (fr) * 2013-09-26 2016-08-03 Energenesis Biomedical Co., Ltd. Composé servant à l'activation de l'ampk et ses utilisations
EP3050567A4 (fr) * 2013-09-26 2017-04-05 Energenesis Biomedical Co., Ltd. Composé servant à l'activation de l'ampk et ses utilisations
AU2013401767B2 (en) * 2013-09-26 2019-05-09 Energenesis Biomedical Co., Ltd Compound for activating ampk and uses thereof
AU2019203668B2 (en) * 2013-09-26 2020-09-10 Energenesis Biomedical Co., Ltd Compound for activating AMPK and uses thereof
EP3769766A1 (fr) * 2013-09-26 2021-01-27 Energenesis Biomedical Co., Ltd. Adenine pour activer ampk et ses utilisations médicales
AU2020244377B2 (en) * 2013-09-26 2022-04-07 Energenesis Biomedical Co., Ltd Compound for activating AMPK and uses thereof

Also Published As

Publication number Publication date
US20090030005A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
US20090030005A1 (en) Combinations for the treatment of cancer
EP2937349B1 (fr) Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et flt3
CA2600195C (fr) Combinaisons destinees au traitement de cancer
TWI394755B (zh) 稠合的雜環衍生物及其使用方法
CN101945867A (zh) 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
US8648199B2 (en) Process for making a solid-state form of AMG 706
US8691838B2 (en) Heterocycles as protein kinase inhibitors
EP1987023B1 (fr) Formes hydrate d'amg706
US7795254B2 (en) Benzomorpholine derivatives and methods of use
JP2014510793A (ja) 集団のサブセットにおける非小細胞肺癌の治療での使用のためのモテサニブ、タキサン、および白金含有抗癌剤の組み合わせ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08780241

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08780241

Country of ref document: EP

Kind code of ref document: A1